BiBBInstruments CEO Fredrik Lindblad
| Published January 7, 2025

BiBBInstruments prepares for market launch – BioStock takes the pulse of the CEO

EndoDrill GI is being evaluated at several clinics around Europe and the US. The company behind the new sampling instrument, BiBBInstruments, is conducting a rights issue of approximately SEK 36,5 million to prepare for the market launch of the product. BioStock has spoken to the company's CEO Fredrik Lindblad to learn more about the plans.

Watch the full interview with BiBBInstruments CEO below.

BioStock is a news service and does not provide investment advice, does not mediate any investment orders and does not take any responsibility for actions and/or any loss or damage of any kind based on the use of content published on BioStock.se. Instead, each investment decision is made independently by the individual investor. The content of BioStock's news and analyses is independent, but as BioStock's operations are partly financed by companies in the industry, the BioStock website may contain news about companies from which BioStock has received funding.

This material has been prepared for marketing purposes and is not and shall not be considered to constitute a prospectus under applicable laws and regulations. The full terms and conditions of the rights issue and further information about the company have been set out in a prospectus which has been published and published on the said company's website.